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Am. J. Physiol. 263 (Cell Physiol. 32): C474-C479, 1992.-We 
examined the effects of insulin-like growth factors (IGFs) and 
insulin on erythropoietin (EPO) production by human hepa- 
toma cells (Hep G2). Compared with normoxia (20% O,), EPO 
production by Hep G2 cells during a 72-h incubation was stim- 
ulated fivefold by exposure to low oxygen tension (1% 0,) and 
nearly threefold by exposure to cobalt chloride (100 PM). IGF-I 
caused a concentration-dependent attenuation of EPO forma- 
tion under normoxic conditions and inhibited (maximally 50%) 
EPO production stimulated by either low oxygen tension or 
cobalt [half-maximal effect (ED& = 5 nM]. The increase of 
EPO mRNA levels in response to hypoxia was significantly 
reduced by IGF-I. Similarly to IGF-I, IGF-II (EDs0 = 8 nM) 
and insulin (EDso = 80 nM) also inhibited EPO formation in 
Hep G2 cells. IGF-I (100 pM--100 nM) stimulated the incorpo- 
ration of radiolabeled alanine as a measure for total protein 
synthesis, 3H-labeled thymidine incorporation into DNA, and 
glycogen synthesis at 20 and 1% 0, in a concentration-depen- 
dent fashion. IGF-I exhibited a high affinity for the IGF-I re- 
ceptor (apparent Kd = 3 nM). Unlabeled insulin was X00-fold 
less potent than IGF-I in competing for lz51-IGF-I binding 
(apparent & ~360 nM). Conversely, insulin bound to the in- 
sulin receptor with high affinity (apparent & = 0.3 nM), 
whereas IGF-I was 4% as potent in competing for 1251-insulin 
binding. In summary, IGFs and insulin exert a negative control 
function on oxygen-regulated EPO production in Hep G2 cells. 
The inhibitory effect of IGFs and insulin on EPO formation 
appears to be mediated via the IGF-I receptor. 
hypoxia; cobalt; radioimmunoassay 
ERYTHROPOIESIS is controlled by the glycoprotein hor- 
mone erythropoietin (EPO), which is predominantly 
produced in the kidneys and to a minor extent in the 
liver (3, 6). Recent studies suggest that insulin-like 
growth factor (IGF) I, the peripheral mediator of growth 
hormone effects (5, 28), may be involved in the regula- 
tion of red cell formation (16, 21). Thus IGF-I stimu- 
lates the proliferation of late erythroid precursors in 
vitro (1, 9, 21), and administration of IGF-I to neonatal 
rats increases erythroid colony (CFUe) formation in the 
bone marrow (16). Furthermore, continuous infusion of 
IGF-I in hypophysectomized rats activates erythropoie- 
sis proportionally to the body growth (11). Part of the 
erythropoietic activity of IGF-I may be mediated by 
EPO because serum EPO levels, which are subnormal in 
hypophysectomized animals, increased markedly to 
even above normal values during IGF-I administration 
(11). Because serum EPO levels closely correlate with 
the rates of de novo EPO synthesis in the organism (23), 
it was concluded that EPO production in hypophysec- 
tomized animals is stimulated by IGF-I. The mecha- 
nism, however, by which IGF-I increased EPO forma- 
tion rates in hypophysectomized animals is unknown. In 
particular, those in vivo studies did not clarify whether 
IGF-I exerted direct effects on EPO-producing cells. 
Studies on the cellular regulation of EPO formation 
are hampered by the fact that the EPO-producing cells 
from neither the liver nor the kidneys could yet be iso- 
lated and studied under controlled in vitro conditions. 
Recently, however, two human hepatoma cell lines (Hep 
G2 and Hep 3B) were found to produce EPO in an 
oxygen- and cobalt-regulated fashion as is characteristic 
of the in vivo situation (4, 15, 24). Hence Hep G2 and 
Hep 3B cells are considered as suitable models for stud- 
ies on the cellular mechanisms of EPO production. 
In the present study we have used Hep G2 cultures to 
examine whether IGF-I has a direct regulatory effect on 
EPO-producing cells. We found that IGF-I, IGF-II, and 
insulin decreased basal (20% 0,) EPO formation in Hep 
G2 cells. Moreover, IGF-I, IGF-II, and, at lo-fold higher 
concentrations, also insulin inhibited hypoxia- and co- 
balt-activated EPO formation in Hep G2 cells in a dose- 
dependent fashion. In competitive binding studies, both 
IGF-I and insulin cross-reacted with each other’s recep- 
tors with affinities ranging X00-fold lower than for 
their own specific binding sites. Taken together, our 
findings suggest that both IGFs and insulin modulate 
EPO production through interacting with the IGF-I re- 
ceptor. 
MATERIALS AND METHODS 
Materials. Q-Minimal essential medium (cr-MEM) was ob- 
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Cellular protein concentration. Cellular protein was taken as 
a measure for cellular mass. It was confirmed that the mean 
cellular protein content was the same under the different exper- 
imental conditions. To this end, the cells were incubated for 24, 
48, and 72 h according to the experimental protocols. Thereafter 
they were trypsinized with 0.1% trypsin (Amimed), and aliquots 
of the cell suspensions were counted in a Neubauer chamber. 
Mean protein content of Hep G2 cells was -320 pug protein/IO” 
cells. For protein determination, the culture medium was re- 
moved and the cell layers were washed twice with 300 ~1 of 
phosphate-buffered saline (PBS). Then 500 ,~l PBS supple- 
mented with 0.1% Triton X-100 was added, and the multiwell 
plates were shaken at room temperature for 30 min. Thereafter 
the samples were centrifuged for 20 min at 4,000 g in a Sorvall 
RT 6000 centrifuge that was cooled to 4°C. Protein content in 
the cell lysates was determined with a commercially available 
protein assay (Bio-Rad) using bovine serum albumin as a stan- 
dard. 
Determination of glycogen synthesis. Glycogen synthesis was 
determined by measuring D- [“HIglucose incorporation into gly- 
cogen as described by Widmer et al. (26). At 24 h after seeding 
at a density of 5 x IO4 cells/cm2, Hep G2 cells were exposed to 
20 and 1% 02, respectively, in culture medium containing 7 mM 
glucose and various concentrations of IGFs or insulin. After 24 
h, the culture medium was replaced and 0.5 &i of D-[‘iH]glucose 
was added to each well. After a 3-h incubation period at 37°C 
the medium was removed and 200 ~1 of 20% KOH containing I 
mg of glycogen was added. The cells were kept at 60°C for 40 
min, and the cell lysates were transferred to tubes and incubated 
at 60°C for 1 h. The tubes were cooled in ice water, and 1 ml of 
cold absolute ethanol (-2OOC) was added. Glycogen was purified 
by centrifugation and two washes with 1 ml of ethanol to which 
20 ~1 of 5% LiBr and 20 ~1 of 1 N KOH had been added (30). 
The final precipitate was dissolved in 0.2 ml of 0.2 N HCl and 
counted in 5 ml of OptiPhase MP (LKB) in a liquid scintillation 
counter. 
Determination of DNA synthesis. Cells were kept in CY-MEM 
containing unlabeled thymidine (10 mg/l) and various concen- 
trations of IGFs and insulin. After 24 h, new medium containing 
I ,&i of [“Hlthymidine was added to each well. Incubation was 
continued for 3 h. Thereafter the cells were rinsed with ice-cold 
PBS, covered with 0.5 ml of ice-cold 10% trichloroacetic acid 
(TCA), and kept at 4°C for 50 min to extract TCA-soluble 
material (22). After the cells were washed three times with cold 
10% TCA, they were dried in an air stream and digested in 0.2 
ml of 1 N KOH. After neutralization with 1 N HCl, radioactiv- 
ity was counted in 5 ml of OptiPhase MP in a beta counter. 
Determination of protein synthesis. Triplicate experiments 
were performed with various concentrations of IGFs and insulin 
in culture medium containing alanine (25 mg/l). After 24 h, the 
medium was replaced and 0.5 &i of [“Hlalanine was added for 
another 3 h. Further processing was the same as described for 
determination of DNA synthesis. 
Determination of EPO. EPO concentrations were deter- 
mined by radioimmunoassay exactly as described (2), except 
that the standards were dissolved in culture medium (a-MEM 
plus 10% fetal calf serum). EPO production rates by Hep G2 
cells are expressed per IO6 cells. 
Ribonuclease protection assay for human EPO mRNA. The 
cRNA probe used in the ribonuclease (RNase) protection assays 
was obtained by using SP6 RNA polymerase from a 154-base 
pair fragment from the Pst I site in exon 3 to the Hind II site in 
exon 4 of the human cDNA. RNase protection assays were 
performed using conditions described by Ratcliffe et al. (18) 
with 50 pug total RNA in each hybridization. 
Binding studies. Competitive binding studies were performed 
according to Widmer et al. (26 j. To this end, Hep G2 cells were 
seeded in multiwell plates at a density of -5 x IO4 cells/cm2. At 
72 h after onset of culture, the medium was removed and re- 
placed by PBS containing 7 mM glucose and 1% bovine serum 
albumin. Iodinated IGF-I (60 PM) or insulin (40 PM) together 
with various amounts of unlabeled peptides were added. Cells 
were incubated at 4°C for 4, 12, 24, and 48 h. Binding of labeled 
ligands reached a maximum after 24 h; therefore 24-h incuba- 
tions were used as a standard protocol. After the incubation 
periods, the cells were rinsed with ice-cold PBS, trypsinized 
with 0.1% trypsin, and transferred into counting vials. Cell- 
associated radioactivity was determined in a gamma counter. 
Presentation of data. Data are expressed as means t SE of 
n experiments. Each experiment represents the mean of qua- 
druplicate wells. 
Statistics. Student’s t test for paired observations was used 
for the evaluation of statistical differences. P < 0.05 was con- 
sidered to be statistically significant. 
RESULTS 
Dose-response curves for oxygen on EPO production 
were performed in the range between 0.5 and 20% O2 in 
the incubation atmosphere and for cobalt between 0 and 
500 PM in the cell culture medium. EPO production rates 
were found to be maximal at 1% O2 and 100 PM cobalt, 
and these conditions were therefore chosen as standard 
stimuli. Cells were seeded at low density of 5 x lo4 cells/ 
cm’, and EPO production rates during 72 h incubation 
were 31 +- 1 mU/lOfi cells at 20% OV (n = 19; Fig. 1). EPO 
formation was 157 t 12 (n = 19) and 85 -t 6 mu/lo6 cells 
(n = 12) at 1% Oc, and at 20% Oz plus 100 PM cobalt, 
respectively (Fig. i). Cell proliferation was significantly 
(P < 0.05) diminished during 72 h exposure to low oxygen 
[cell number 0.98 t 0.1 x 10” cells/cm’ at 1% Oz (n = 19) 
vs. 1.2 + 0.1 x lot5 cells/cm” at 20% O2 (n = 19)] and 
slightly-but not significantly (P > 0.05) increased by 
100 yM cobalt [cell number 1.3 t 0.1 X 10” cells/cm” 
(n = 12)]. 
Addition of IGF-I to the culture medium during the 72 
h of the experiment led to a concentration-dependent 
inhibition of EPO production at high and low oxygen 
tensions and in the presence of cobalt (Fig. 1A). IGF-I did 
not completely suppress the increase of EPO production 
in response to low oxygen tension and cobalt but con- 
stantly reduced hypoxia- and cobalt-stimulated EPO for- 
mation maximally by 50% (Fig. 1). The half-maximal 
effect of IGF-I on EPO production was obtained at a 
IGF-I concentration [half-maximal effect (ED,,)] of 5 
nM, which was nearly the same at 20% 02, 1% 02, and 
20% O2 plus 100 PM cobalt chloride (Fig. 1). IGF-I-in- 
duced inhibition of EPO formation was associated with a 
~50% reduction of EPO mRNA accumulation in re- 
sponse to hypoxia (Fig. 2). IGF-I did not measurably 
affect EPO mRNA levels at 20% O2 (Fig. 2). 
To test whether the inhibitory action on EPO produc- 
tion was specific for IGF-I, we also examined the effects 
of IGF-II and insulin, which are structurally related to 
IGF-I (5, 19). Like IGF-I, IGF-II and insulin caused a 
concentration-dependent inhibition of EPO formation 
(Fig. 1, B and C). EDf,o values were obtained with 8 and 
80 nM of IGF-II and insulin, respectively (Fig. 1). Similar 
to IGF-I, saturating concentrations of IGF-II and insulin 
caused a reduction of EPO formation by somewhat less 
than 50% of control (Fig. 1). 
In addition to its inhibitory action on EPO production, 
C476 IGF AND ERYTHROPOIETIN PRODUCTION 
B- 
IGF-I (M) 
Insulin (M) 
Fig. 1. Dose-response curves for insulin-like growth factor (IGF) I (A) 
and II (B) and insulin (C) on erythropoietin (EPO) production by Hep 
G2 cells. Cells were incubated for 72 hat 20% O2 (o), 1% O2 (a), and 20% 
O2 plus 100 PM CoCla (0) with the culture medium (o-minimal essential 
medium + 10% fetal calf serum) containing various concentrations of 
hormones. EPO formation rates are expressed per lo6 cells. Values are 
means + SE of n = 8 experiments, each performed in quadruplicate 
wells. * Statistically different from control (P c 0.05). 
IGF-I (100 pM-100 nM) also increased [3H]alanine in- 
corporation into protein at 20 and 1% O2 in a concentra- 
tion-dependent fashion (Fig. 3). IGF-I-induced stimula- 
tion of protein synthesis was paralleled by increased 
[3H]thymidine incorporation into DNA (Fig. 3). More- 
over, IGF-I stimulated the incorporation of D-[3H]glu- 
case into glycogen. IGF-I was more effective in stimulat- 
ing glycogen synthesis under hypoxic than under 
normoxic conditions (Fig. 3). Similar to IGF-I, IGF-II 
(l-100 nM) and insulin (10 nM-1 PM) also significantly 
increased Hep G2 cell proliferation and glycogen synthe- 
sis at 20 and 1% 0s (not shown). 
Hep G2 cells express distinct receptors for IGFs and 
insulin on their cell membranes that cross-react with 
each other’s specific ligand with reduced affinities (17, 
25). By comparing their relative binding affinities, one 
Fig. 2. RNase protection analysis of mRNA from Hep G2 cells. EPO 
signals are indicated by arrow. Size markers were generated by a Hpa II 
digest of pBR322 DNA. Protected bands were excised from gel, set in a 
solid scintillant, and counted in a beta counter. IGF-I concentration 
used was 10 nM. cpm, counts/min. 
may therefore distinguish whether IGF-I and insulin in- 
hibited EPO production by reacting with the same recep- 
tor type or with their own specific binding sites. Using 
intact Hep G2 cells, binding affinities were found to be 
the same at 20 and 1% Oz. Total binding of 1251-IGF-I 
was 4.8%, and nonspecific binding was <lo% of total 
binding (Fig. 4). Nonspecific binding of 1251-IGF-I was 
determined in the presence of saturating concentrations 
(10 PM) of unlabeled ligand. Half-maximal displacement 
of specific 1251-IGF-I binding was obtained with 0.5 nM 
of unlabeled IGF-I, whereas -20-fold-higher concentra- 
tions of IGF-II and nearly 600-fold-higher concentrations 
of insulin were required (Fig. 4). From Scatchard plot 
analysis, the affinity constant of the IGF-I receptor for 
IGF-I was found to be 3 nM at high and low oxygen 
tensions. Total binding of 1251-insulin was 20%, and non- 
specific binding was <lo% of total binding (Fig. 5). The 
50% inhibition of specific 1251-insulin binding was 
achieved with 0.5 nM of unlabeled ligand, whereas -60 
nM IGF-I was necessary for half-maximal displacement 
of bound 1251-insulin (Fig. 5). Insulin (100 pM-10 PM) 
did not inhibit specific 1251-IGF-II binding (not shown). 
DISCUSSION 
IGF-I, the peripheral mediator of growth hormone ef- 
fects (5, 28), has recently been found to stimulate EPO 
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Fig. 3. Concentration-dependent stimulation of protein and DNA syn- 
thesis and of [“HIglucose incorporation into glycogen (a) by IGF-I. 
[“Hlalanine (0) and [“HI thymidine (0) incorporation into TCA-precip- 
itable material were taken as a measure for protein and DNA synthesis, 
respectively. Experiments were performed at 20 (A) and 1% 0, (B). 
Values are means t SE of 5 different experiments, each performed in 
quadruplicate wells. * Significantly different from control (P < 0.05). 
Competing ligand (M) 
Fig. 4. Competitive inhibition of binding of 12sI-IGF-I to Hep G2 cells 
by unlabeled IGF-I (o), IGF-II (A), and insulin (0). Cells were incubated 
under normoxic conditions (20% 0,) at 4°C for 24 h in phosphate- 
buffered saline (PBS) containing 7 mM glucose and 1% bovine serum 
albumin together with 60 pM iodinated IGF-I and various amounts of 
unlabeled hormones. Total binding per lo5 cells is plotted as percentage 
of added radioactivity against concentration of unlabeled ligands. No 
significant differences were found between 12!I-IGF binding at 20 and 
1% 0, (not shown). Values are means of 3 representative experiments, 
each performed in quadruplicate wells. 
formation in hypophysectomized rats (11). The mecha- 
nism, however, by which IGF-I increased EPO produc- 
tion in hypophysectomized animals is unknown. In par- 
ticular it is unclear whether IGF-I exerted a direct effect 
on EPO-producing cells in the kidneys or in the liver. In 
the present study we have therefore examined whether 
IGF-I directly modulates EPO formation at the cellular 
level. 
To our knowledge, highly enriched preparations of 
EPO-producing cells from neither the kidneys nor the 
Competing ligand (M) 
Fig. 5. Displacement of 12”1-insulin binding by unlabeled insulin (o), 
IGF-I (o), and IGF-II (A). Hep G2 cells were incubated in an atmosphere 
of 20% O2 at 4°C for 24 h. Iodinated insulin (40 PM) and various 
amounts of unlabeled hormones were added to the incubation solution 
(PBS containing 7 mM glucose and 1% bovine serum albumin). Cell- 
associated radioactivity was determined in a gamma counter. No sig- 
nificant differences of ““I-insulin binding were found between incuba- 
tion at 20 and 1% 0, (not shown). Values are means of 3 representative 
experiments, each performed in quadruplicate wells. 
liver are yet available as primary cultures. In view of those 
circumstances, we have used the human hepatoma cells 
Hep G2 (8), which not only (like the intact organism) 
produce EPO in an oxygen- and cobalt-regulated fashion 
(4, 15, 24) but also express distinct cell surface receptors 
for IGFs and insulin (17, 25). 
We found that IGF-I (30 pM-3 nM) inhibited EPO 
formation at 20 and 1% OZ and in the presence of cobalt 
chloride with an EDSo value of 5 nM (Fig. IA). IGF-I- 
induced inhibition of EPO formation was, at least in part, 
due to decreased EPO gene transcription, because EPO 
mRNA accumulation in response to hypoxia was signif- 
icantly reduced by IGF-I (Fig. 2). IGF-II inhibited EPO 
formation nearly with the same potency as IGF-I did 
(EDSo 8 nM), whereas the insulin concentration required 
to decrease EPO production half maximally was 80 nM 
(Fig. 1, B and C). 
If we assume that IGFs and insulin specifically de- 
creased EPO formation in Hep G2 cells, then one should 
expect that their effects were due to a direct interaction 
with specific cell membrane receptors. Hep G2 cells ex- 
press distinct receptors for IGF-I and insulin on their cell 
surface (17, 25), and part of those binding sites has re- 
cently been found to be hybrids composed of an IGF-I 
and an insulin receptor a-@-heterodimer (14). First evi- 
dence for which of those receptor types were mediating 
the inhibitory effects of IGFs and insulin on EPO pro- 
duction can be obtained by comparing their relative bind- 
ing affinities. To this end we performed competitive 
binding studies, and we found that the apparent & 
(3 nM) for IGF-I binding to its own specific receptor was 
nearly the same as the EDSo value (5 nM) for IGF-I- 
induced inhibition of EPO formation. In conclusion, 
IGF-I exerted its effects most likely through an interac- 
tion with the IGF-I receptor. For comparison, the Kd 
(~0.3 nM) for the binding of insulin to its specific recep- 
tor was X5-fold lower than the insulin concentration 
required to reduce EPO secretion half maximally (80 
nM). Therefore it appears rather unlikely that insulin 
decreased EPO production by populating its own specific 
binding site. However, comparing the dose-response 
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curves for insulin with the relatively low affinity of insu- 
lin for the IGF-I receptor (apparent Kd = 360 nM), our 
findings strongly suggest that insulin reduced EPO for- 
mation by cross-reacting with the IGF-I receptor. 
For the following lines of evidence we think that the 
inhibitory effect of IGF-I on EPO production was due to 
a specific rather than an unspecific (toxic) action on Hep 
GZ cells. First, IGF-I stimulated protein synthesis in Hep 
G2 cells in a concentration-dependent fashion at high 
and low oxygen tensions (Fig. 3). In conclusion, decreased 
EPO gene expression did not result from an overall inhi- 
bition of protein synthesis caused by IGF-I. Second, 
IGF-I still exerted some other characteristic effects such 
as a dose-dependent increase of DNA synthesis and gly- 
cogen formation (Fig. 3). 
The question arises about the cellular mechanism by 
which IGF-I reduced EPO production in Hep G2 cells. It 
is fairly established that the IGF-I receptor acts as a 
tyrosine kinase (13), and it is reasonable, therefore, to 
assume that such a phosphorylation step is also involved 
in the action of IGF-I on EPO formation by Hep G2 cells. 
An interesting action of IGF’s action in this context was 
that it only partially inhibited EPO production (Fig. 1). 
Such a partial decrease of stimulated EPO production by 
Hep G2 cells has recently also been found for cytokines 
such as tumor necrosis factor-a and interleukin-I (7). 
Like IGF-I, tumor necrosis factor-a and interleukin-1 are 
also thought to act via specific kinases (12, 20). It is not 
unlikely, therefore, that IGF-I and cytokines have the 
same target for phosphorylation in the cascade control- 
ling oxygen-regulated EPO production. It remains to be 
clarified whether specific cellular effects of IGF-I such as 
stimulation of glycogen synthesis (Fig. 3) or increased 
amino acid uptake (25) were indirectly involved in its 
inhibitory action on EPO gene expression. 
In summary, we found that IGFs and insulin decreased 
oxygen- and cobalt-regulated EPO formation in Hep G2 
cells, and those effects were at least in part due to de- 
creased EPO gene transcription. Moreover, our findings 
also suggest that both IGFs and insulin inhibited EPO 
production through a specific interaction with the IGF-I 
receptor. 
In asking for the potential physiological relevance of 
those findings obtained with hepatoma cells, the answer 
is based upon the assumption that the signal transduction 
mechanisms for oxygen-regulated EPO formation are 
similar in Hep G2 cells and in normal hepatocytes. Be- 
cause primary cultures of hepatocytes that produce EPO 
in a regulated fashion have not yet been established, there 
is at present no possibility to prove or disprove this as- 
sumption. Within the limits of the experimental model 
that was used in this study, one should expect that he- 
patic EPO production is inhibited when the liver in- 
creases its IGF-I formation, a situation that occurs dur- 
ing the first weeks after birth (10). Because EPO 
production is known to shift from the liver to the kidneys 
during this time period (27), we can speculate that IGF-I 
could play a role in this organ shift, which is yet unex- 
plained. 
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